Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells

Nature

Volumn 475, Issue 7355, 2011, Pages 226-230

  Facciabene, Andrea ^a   Peng, Xiaohui ^a   Hagemann, Ian S ^a   Balint, Klara ^a   Barchetti, Andrea ^a   Wang, Li Ping ^a   Gimotty, Phyllis A ^a   Gilks, C Blake ^b   Lal, Priti ^a   Zhang, Lin ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCL28; UNCLASSIFIED DRUG;

CYTOLOGY; HYPOXIA; IMMUNE SYSTEM; MOLECULAR ANALYSIS; TUMOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CHEMOKINES, CC; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTORS, CCR10; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960393113     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10169     Document Type: Article

References (37)

1. Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007). (Pubitemid 350231320)
2. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003). (Pubitemid 36077915)
3. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005). (Pubitemid 40488632)
4. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. NatureMed. 10, 942-949 (2004). (Pubitemid 39273735)
5. Nagaraj, S.&Gabrilovich, D. I.Myeloid-derived suppressor cells. Adv. Exp.Med. Biol. 601, 213-223 (2007).
6. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008). (Pubitemid 351430364)
7. Buckanovich, R. J. et al. EndothelinBreceptormediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Med. 14, 28-36 (2008).
8. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996). (Pubitemid 26338628)
9. Li, B. et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808-6816 (2006). (Pubitemid 44876851)
10. Osada, T. et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115-1124 (2008).
11. Lotfi, R., Lee, J. J. & Lotze, M. T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 30, 16-28 (2007). (Pubitemid 46052200)
12. Shimogai, R. et al. Expression of hypoxia-inducible factor 1a gene affects the outcomein patientswithovarian cancer. Int. J. Gynecol. Cancer 18, 499-505 (2008). (Pubitemid 351668322)
13. Daponte, A. et al. Prognostic significance of hypoxia-inducible factor 1a (HIF-1a) expression in serous ovarian cancer: animmunohistochemical study.BMC Cancer 8, 335 (2008).
14. Pan, J. et al. Anovel chemokine ligandforCCR10andCCR3expressed by epithelial cells in mucosal tissues. J. Immunol. 165, 2943-2949 (2000).
15. Feng, N. et al. Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA1 plasmablast recruitment to the intestinal lamina propria after rotavirus infection. J. Immunol. 176, 5749-5759 (2006).
16. Eksteen, B. et al. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J. Immunol. 177, 593-603 (2006). (Pubitemid 43939173)
17. Wang, W. et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J. Biol. Chem. 275, 22313-22323 (2000). (Pubitemid 30621816)
18. Lazarus, N. H. et al. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J. Immunol. 170, 3799-3805 (2003). (Pubitemid 36359249)
19. Roby, K. F. et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21, 585-591 (2000). (Pubitemid 30214011)
20. Zhang, L. et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161, 2295-2309 (2002). (Pubitemid 35434873)
21. Elia, L. et al. CD41CD251 regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. 14, 201-210 (2007). (Pubitemid 46106963)
22. Kandalaft, L. E., Facciabene, A., Buckanovich, R. J. & Coukos, G. Endothelin B receptor, a newtarget in cancer immune therapy. Clin. Cancer Res. 15, 4521-4528 (2009).
23. Buckanovich, R. J. et al. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol. 25, 852-861 (2007). (Pubitemid 350002886)
24. Ohta, A. et al.A2A adenosine receptor protects tumors fromantitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006). (Pubitemid 44338928)
25. Ben-Shoshan, J., Maysel-Auslender, S., Mor, A., Keren, G. & George, J. Hypoxia controls CD41CD251 regulatory T-cell homeostasis via hypoxia-inducible factor- 1a. Eur. J. Immunol. 38, 2412-2418 (2008).
26. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9, 562-567 (2003). (Pubitemid 36597102)
27. Yang, L. et al. Expansion of myeloid immune suppressor Gr1CD11b1 cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). (Pubitemid 39361441)
28. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b1Gr11 myeloid cells. Nature Biotechnol. 25, 911-920 (2007). (Pubitemid 47236916)
29. Curiel, T. J. et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535-5538 (2004). (Pubitemid 39095544)
30. Bertozzi, C. C. et al. Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell. Dev. Biol. Anim. 42, 58-62 (2006). (Pubitemid 44264507)
31. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006). (Pubitemid 43128862)
32. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008).
33. Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252-7259 (2004). (Pubitemid 39487712)
34. Bergeron, M. et al. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia. Neuroscience 89, 1357-1366 (1999). (Pubitemid 29074651)
35. Lee, O. H. et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 264, 743-750 (1999).
36. Lee, Y. H. et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur. J. Cancer 35, 1089-1093 (1999). (Pubitemid 29339192)
37. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).